-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Avadel Pharmaceuticals Plc quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2019 to 2024.
- Avadel Pharmaceuticals Plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was -$27.2M, a 13.1% increase year-over-year.
- Avadel Pharmaceuticals Plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2024 was -$157M, a 39.8% decline year-over-year.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly Data (USD)